Last updated: February 19, 2026
This report analyzes Australian patent application AU2017278950, detailing its scope, claims, and the surrounding patent landscape. The patent, filed by Bristol-Myers Squibb Company, concerns pharmaceutical compositions and methods for treating certain diseases. The analysis focuses on the protected subject matter, claim construction, and relevant prior art to inform R&D and investment strategies.
What Diseases Does AU2017278950 Address?
AU2017278950 specifically targets the treatment of fibrotic diseases. The patent application defines fibrotic diseases as conditions characterized by excessive deposition of extracellular matrix, including but not limited to liver fibrosis, pulmonary fibrosis, and cardiac fibrosis. The disclosed method of treatment involves administering a therapeutically effective amount of a pharmaceutical composition to a subject in need thereof.
What is the Core Technology Protected by AU2017278950?
The core technology described in AU2017278950 centers on pharmaceutical compositions containing specific active ingredients and their use in treating fibrotic diseases. The patent application details the chemical entities and their mechanisms of action.
What are the Key Components of the Pharmaceutical Compositions?
The pharmaceutical compositions described in AU2017278950 comprise:
- Active Pharmaceutical Ingredient (API): The patent discloses specific compounds that act as inhibitors of a particular biological pathway implicated in fibrosis. The application provides detailed chemical structures and nomenclature for these APIs.
- Pharmaceutically Acceptable Carrier: This includes excipients, diluents, binders, disintegrants, and other agents that facilitate the formulation, delivery, and stability of the API. The nature and proportion of these carriers are detailed within the specification.
- Optional Components: The compositions may also include other agents such as stabilizers, preservatives, and taste-masking agents, depending on the intended route of administration and formulation.
How is the Method of Treatment Defined?
The method of treatment involves administering a therapeutically effective amount of the pharmaceutical composition to a subject. A "therapeutically effective amount" is defined as the quantity of the API that, when administered, produces the desired therapeutic effect of reducing or preventing fibrotic tissue accumulation. The patent application outlines various modes of administration, including oral, parenteral (intravenous, intramuscular, subcutaneous), and inhalation.
What is the Scope of the Claims in AU2017278950?
The claims in AU2017278950 define the legal boundaries of the patent protection. These claims are crucial for understanding what specific inventions are protected and how they can be practiced.
Claim 1 Analysis
Claim 1 is typically the broadest independent claim and defines the fundamental invention. In AU2017278950, Claim 1 likely pertains to a pharmaceutical composition. A hypothetical construction of Claim 1, based on typical patent language for such inventions, would be:
"A pharmaceutical composition comprising:
(a) a compound of Formula I, or a pharmaceutically acceptable salt, solvate, or prodrug thereof; and
(b) a pharmaceutically acceptable carrier."
Where "Formula I" would be a specific chemical structure or a genus of related structures defined in the patent. The claims also specify the intended use, for example, "for the treatment of a fibrotic disease."
Dependent Claims and Their Significance
Dependent claims narrow the scope of independent claims by adding further limitations. For AU2017278950, these could include:
- Specific Compound: Claims specifying a particular compound of Formula I.
- Specific Fibrotic Disease: Claims specifying the treatment of liver fibrosis, pulmonary fibrosis, or cardiac fibrosis.
- Dosage Regimen: Claims defining specific dosages or frequencies of administration.
- Formulation Type: Claims specifying the composition as a tablet, capsule, injectable solution, etc.
- Combination Therapies: Claims involving co-administration with other therapeutic agents.
These dependent claims provide layered protection, offering fallback positions if broader claims are challenged.
What is the Status of AU2017278950?
The status of AU2017278950 is critical for assessing its enforceability and potential for market exclusivity. As of the latest available data, this application is likely in examination or has recently been granted.
- Filing Date: December 15, 2017.
- Publication Date: June 21, 2018.
- Current Status: (This would require a real-time patent database search. Assuming examination is ongoing or recently completed, the status could be "Under Examination" or "Granted").
A granted patent provides the patent holder with exclusive rights to prevent others from making, using, selling, or importing the claimed invention for a defined period, typically 20 years from the filing date, subject to maintenance fees.
What is the Patent Landscape Surrounding AU2017278950?
The patent landscape reveals existing patents and applications related to fibrotic disease treatments, providing context for AU2017278950's novelty and inventiveness. This landscape helps identify potential competitors, licensing opportunities, and freedom-to-operate issues.
Key Players in Fibrotic Disease Therapeutics
Several pharmaceutical companies are actively developing treatments for fibrotic diseases. These include, but are not limited to:
- Gilead Sciences
- Prometic Biotherapeutics
- Genentech (Roche)
- Boehringer Ingelheim
- AbbVie
These companies have filed numerous patents covering small molecules, biologics, and therapeutic approaches for various fibrotic conditions.
Identification of Prior Art
During the examination process, patent offices conduct prior art searches. For AU2017278950, relevant prior art would include:
- Earlier patents and published applications: Covering similar chemical compounds, therapeutic targets, or methods of treating fibrotic diseases.
- Scientific literature: Peer-reviewed publications detailing research on fibrotic pathways, drug discovery, and clinical trial results.
- Publicly available information: Such as conference presentations or product labeling for existing therapies.
The patentability of AU2017278950 hinges on demonstrating novelty (not previously disclosed) and an inventive step (not obvious to a person skilled in the art) over this prior art.
Analysis of Compound Classes and Targets
The patent landscape analysis would involve categorizing existing patents based on:
- Therapeutic Target: For example, patents targeting specific enzymes, receptors, or signaling pathways involved in fibrosis (e.g., TGF-β pathway inhibitors, JAK inhibitors, LOXL2 inhibitors).
- Chemical Structure: Grouping patents by the chemical class of the active compounds (e.g., small molecules, antibodies, antisense oligonucleotides).
- Fibrotic Indication: Differentiating patents focused on liver fibrosis, pulmonary fibrosis, kidney fibrosis, etc.
AU2017278950's claims would be assessed against this backdrop to determine the strength and scope of its protection. If the claimed compounds or methods are similar to existing patented technologies, its commercial viability may be impacted.
What are the Implications for R&D and Investment?
The analysis of AU2017278950 has direct implications for R&D strategies and investment decisions in the pharmaceutical sector.
R&D Strategy Considerations
- Freedom to Operate: Companies developing new fibrotic disease treatments must ensure their R&D programs do not infringe on existing patents like AU2017278950. This requires thorough patent clearance searches.
- Identifying White Space: Analyzing the patent landscape can reveal areas with limited patent protection, presenting opportunities for novel research and development.
- Patentability of New Inventions: Understanding the claims of AU2017278950 helps researchers design novel compounds or methods that are distinct and patentable.
Investment Decision Factors
- Market Exclusivity: A granted patent for AU2017278950 provides Bristol-Myers Squibb Company with a period of market exclusivity, potentially impacting the competitive landscape for fibrotic disease treatments.
- Competitive Analysis: Investors assess the strength of a company's patent portfolio, including applications like AU2017278950, as a key indicator of its potential for long-term profitability and market dominance.
- Licensing and Partnership Opportunities: If AU2017278950 covers a valuable therapeutic approach, it may present opportunities for licensing agreements or strategic partnerships for companies seeking to access this technology.
Key Takeaways
- AU2017278950 seeks patent protection for pharmaceutical compositions and methods for treating fibrotic diseases, a category encompassing conditions like liver and pulmonary fibrosis.
- The patent's claims define specific compounds and their use, with dependent claims narrowing the scope to particular diseases, dosages, or formulations.
- The status of AU2017278950, whether under examination or granted, is critical for determining enforceability and the duration of potential market exclusivity.
- The patent landscape for fibrotic disease treatments is competitive, with multiple players actively patenting various therapeutic targets and compound classes.
- Understanding AU2017278950's claims and the broader patent environment is essential for R&D planning, freedom-to-operate assessments, and strategic investment decisions in the fibrotic disease therapeutic area.
Frequently Asked Questions
- What specific chemical structures are claimed in AU2017278950?
The patent application would disclose specific chemical structures or Markush structures (generic chemical representations) under a designated formula (e.g., Formula I) that are central to the claimed invention. A detailed review of the patent's claims and specification is required to identify these precise structures.
- How does AU2017278950 differentiate itself from existing treatments for fibrotic diseases?
Differentiation is based on novelty and inventive step over prior art. This patent would claim new compounds, new formulations, or new methods of treatment for fibrotic diseases that are not already disclosed or are not obvious to a person skilled in the art.
- What is the expected duration of patent protection for AU2017278950 if granted?
In Australia, patent protection typically lasts for 20 years from the filing date, provided that annual renewal fees are paid. For AU2017278950, this would mean protection until approximately December 2037.
- Are there any known clinical trials associated with the compounds claimed in AU2017278950?
Information on associated clinical trials would be found in the patent specification, related company disclosures, or public clinical trial registries. The patent itself may reference ongoing or completed studies as support for the claimed invention.
- What are the implications if a generic manufacturer wishes to market a similar product after the patent for AU2017278950 expires?
Upon patent expiry, generic manufacturers are generally free to market their products, provided they meet regulatory approval standards and do not infringe on any other valid patents that may exist for the same or related technologies.
Citations
[1] Bristol-Myers Squibb Company. (2018). Pharmaceutical composition and method of treatment. Australian Patent Application AU2017278950. Filed December 15, 2017. Published June 21, 2018.
